Cargando…

First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi

Effective salvage options inducing high complete metabolic response (CMR) rates without significant toxicity are needed for Hodgkin lymphoma (HL) patients failing induction treatment and who are candidate to autologous stem cell transplantation (ASCT). Brentuximab vedotin (BV) and bendamustine are a...

Descripción completa

Detalles Bibliográficos
Autores principales: Broccoli, A., Argnani, L., Botto, B., Corradini, P., Pinto, A., Re, A., Vitolo, U., Fanti, S., Stefoni, V., Zinzani, P. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906387/
https://www.ncbi.nlm.nih.gov/pubmed/31827067
http://dx.doi.org/10.1038/s41408-019-0265-x
_version_ 1783478335552094208
author Broccoli, A.
Argnani, L.
Botto, B.
Corradini, P.
Pinto, A.
Re, A.
Vitolo, U.
Fanti, S.
Stefoni, V.
Zinzani, P. L.
author_facet Broccoli, A.
Argnani, L.
Botto, B.
Corradini, P.
Pinto, A.
Re, A.
Vitolo, U.
Fanti, S.
Stefoni, V.
Zinzani, P. L.
author_sort Broccoli, A.
collection PubMed
description Effective salvage options inducing high complete metabolic response (CMR) rates without significant toxicity are needed for Hodgkin lymphoma (HL) patients failing induction treatment and who are candidate to autologous stem cell transplantation (ASCT). Brentuximab vedotin (BV) and bendamustine are active monotherapies in the relapsed/refractory setting and their combination (the BBV regimen) possibly enhances their activity. This single-arm multicenter phase 2 study investigated the efficacy and safety of BBV as first salvage therapy in 40 patients with relapsed/refractory HL. Thirty-eight patients were evaluable for efficacy: 30 (78.9%) had a CMR and 2 (5.3%) a partial response, leading to an overall response rate (ORR) of 84.2%. The ORR in the primary refractory subset was 75.0%, among relapsed patients it was 94.4%. Thirty-five patients could mobilize peripheral blood stem cells and 33 underwent ASCT. At a median follow-up of 23 months, the estimated 3-year overall survival and progression-free survival are 88.1% and 67.3%. During therapy, only 3 grade IV cases of neutropenia occurred and resolved within a week. No grade 4 extrahematologic toxicities were reported; skin reactions were however rather frequent (65%). These results suggest that the BBV regimen exhibits promising efficacy and a manageable toxicity in a challenging subpopulation of HL patients.
format Online
Article
Text
id pubmed-6906387
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-69063872019-12-13 First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi Broccoli, A. Argnani, L. Botto, B. Corradini, P. Pinto, A. Re, A. Vitolo, U. Fanti, S. Stefoni, V. Zinzani, P. L. Blood Cancer J Article Effective salvage options inducing high complete metabolic response (CMR) rates without significant toxicity are needed for Hodgkin lymphoma (HL) patients failing induction treatment and who are candidate to autologous stem cell transplantation (ASCT). Brentuximab vedotin (BV) and bendamustine are active monotherapies in the relapsed/refractory setting and their combination (the BBV regimen) possibly enhances their activity. This single-arm multicenter phase 2 study investigated the efficacy and safety of BBV as first salvage therapy in 40 patients with relapsed/refractory HL. Thirty-eight patients were evaluable for efficacy: 30 (78.9%) had a CMR and 2 (5.3%) a partial response, leading to an overall response rate (ORR) of 84.2%. The ORR in the primary refractory subset was 75.0%, among relapsed patients it was 94.4%. Thirty-five patients could mobilize peripheral blood stem cells and 33 underwent ASCT. At a median follow-up of 23 months, the estimated 3-year overall survival and progression-free survival are 88.1% and 67.3%. During therapy, only 3 grade IV cases of neutropenia occurred and resolved within a week. No grade 4 extrahematologic toxicities were reported; skin reactions were however rather frequent (65%). These results suggest that the BBV regimen exhibits promising efficacy and a manageable toxicity in a challenging subpopulation of HL patients. Nature Publishing Group UK 2019-12-11 /pmc/articles/PMC6906387/ /pubmed/31827067 http://dx.doi.org/10.1038/s41408-019-0265-x Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Broccoli, A.
Argnani, L.
Botto, B.
Corradini, P.
Pinto, A.
Re, A.
Vitolo, U.
Fanti, S.
Stefoni, V.
Zinzani, P. L.
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
title First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
title_full First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
title_fullStr First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
title_full_unstemmed First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
title_short First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
title_sort first salvage treatment with bendamustine and brentuximab vedotin in hodgkin lymphoma: a phase 2 study of the fondazione italiana linfomi
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906387/
https://www.ncbi.nlm.nih.gov/pubmed/31827067
http://dx.doi.org/10.1038/s41408-019-0265-x
work_keys_str_mv AT broccolia firstsalvagetreatmentwithbendamustineandbrentuximabvedotininhodgkinlymphomaaphase2studyofthefondazioneitalianalinfomi
AT argnanil firstsalvagetreatmentwithbendamustineandbrentuximabvedotininhodgkinlymphomaaphase2studyofthefondazioneitalianalinfomi
AT bottob firstsalvagetreatmentwithbendamustineandbrentuximabvedotininhodgkinlymphomaaphase2studyofthefondazioneitalianalinfomi
AT corradinip firstsalvagetreatmentwithbendamustineandbrentuximabvedotininhodgkinlymphomaaphase2studyofthefondazioneitalianalinfomi
AT pintoa firstsalvagetreatmentwithbendamustineandbrentuximabvedotininhodgkinlymphomaaphase2studyofthefondazioneitalianalinfomi
AT rea firstsalvagetreatmentwithbendamustineandbrentuximabvedotininhodgkinlymphomaaphase2studyofthefondazioneitalianalinfomi
AT vitolou firstsalvagetreatmentwithbendamustineandbrentuximabvedotininhodgkinlymphomaaphase2studyofthefondazioneitalianalinfomi
AT fantis firstsalvagetreatmentwithbendamustineandbrentuximabvedotininhodgkinlymphomaaphase2studyofthefondazioneitalianalinfomi
AT stefoniv firstsalvagetreatmentwithbendamustineandbrentuximabvedotininhodgkinlymphomaaphase2studyofthefondazioneitalianalinfomi
AT zinzanipl firstsalvagetreatmentwithbendamustineandbrentuximabvedotininhodgkinlymphomaaphase2studyofthefondazioneitalianalinfomi
AT firstsalvagetreatmentwithbendamustineandbrentuximabvedotininhodgkinlymphomaaphase2studyofthefondazioneitalianalinfomi